Abstract

As one of the most malignant cancer types, hepatocellular carcinoma (HCC) is highly invasive and capable of metastasizing to distant organs. Intermedin (IMD), an endogenous peptide belonging to the calcitonin family, has been suggested playing important roles in cancer cell survival and invasion, including in HCC. However, how IMD affects the behavior of HCC cells and the underlying mechanisms have not been fully elucidated. Here, we show that IMD maintains an important homeostatic state by activating the ERK1/2-EGR1 (early growth response 1) signaling cascade, through which HCC cells acquire a highly invasive ability via significantly enhanced filopodia formation. The inhibition of IMD blocks the phosphorylation of ERK1/2, resulting in EGR1 downregulation and endoplasmic reticulum stress (ER) stress, which is evidenced by the upregulation of ER stress marker DDIT3 (DNA damage-inducible transcript 3). The high level of DDIT3 induces HCC cells into an ER-stress related apoptotic pathway. Along with our previous finding that IMD plays critical roles in the vascular remodeling process that improves tumor blood perfusion, IMD may facilitate the acquisition of increased invasive abilities and a survival benefit by HCC cells, and it is easier for HCC cells to obtain blood supply via the vascular remodeling activities of IMD. According to these results, blockade of IMD activity may have therapeutic potential in the treatment of HCC.

Details

Title
Intermedin facilitates hepatocellular carcinoma cell survival and invasion via ERK1/2-EGR1/DDIT3 signaling cascade
Author
Xiao Fei 1 ; Li, Hongyu 2 ; Feng Zhongxue 3 ; Huang, Luping 3 ; Kong Lingmiao 3 ; Li, Min 3 ; Wang Denian 3 ; Liu, Fei 4 ; Zhu, Zhijun 2 ; Wei Yong’gang 4 ; Zhang, Wei 3 

 Sichuan University, Department of Intensive Care Unit of Gynecology and Obstetrics, West China Second University Hospital, Chengdu, People’s Republic of China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581) 
 Capital Medical University, Liver Transplantation Center, Beijing Friendship Hospital, Beijing, People’s Republic of China (GRID:grid.24696.3f) (ISNI:0000 0004 0369 153X) 
 Sichuan University and Collaborative Innovation Center of Biotherapy, Department of Critical Care Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Chengdu, People’s Republic of China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581) 
 Sichuan University, Department of Liver Surgery, West China Hospital, Chengdu, People’s Republic of China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2477092393
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.